Evidence mapPaperPMID 9727886Full record

ArticleDiabetes care1998

Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

H King, R E Aubert, W H Herman

12 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Diabetes care, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 12 registered trials, which are not on this map. Cited by 1,225 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,225citing papers in PubMed, 8 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02694263 phase4completedstarted 2016, after this paper: background citation

A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study

Ran2016Enrolled25Registered outcomes32Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsCanagliflozin, Gliclazide, Glimepiride, Pioglitazone, Repaglinide
Open the trial in the graph
NCT03004612 phase4completedstarted 2016, after this paper: background citation

Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial

Ran2016Enrolled144Registered outcomes5Posted comparisons0ConditionsInsulin Resistance, Prediabetic StateArmsLinagliptin + metformin, Metformin
Open the trial in the graph
NCT03693560 phase4completedstarted 2018, after this paper: background citation

The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases

Ran2018Enrolled80Registered outcomes7Posted comparisons0ConditionsCoronary Artery Disease, Diabetes Mellitus, Type 2ArmsGlimepiride upto 4 mg Oral Tablet, Metformin 1000 mg Oral Tablet, Vildagliptin 50 mg Oral Tablet
Open the trial in the graph
NCT04134650 phase3unknown statusstarted 2019, after this paper: background citation

Effect of Low Dose Combination of Linagliptin and Metformin to Improve Pancreatic Beta Cell Function, Insulin Resistance and Cardiovascular Function in Patients With Prediabetes and Overweight/Obesity: Randomizer Clinical Trial

Ran2019Enrolled34Registered outcomes3Posted comparisons0ConditionsInsulin Resistance, Prediabetic StateArmsLinagliptin + metformin, Metformin
Open the trial in the graph
NCT00094796 phase2completednot on this mapstarted 2004, after this paper: background citation

Evaluation of Rosiglitazone in Reversing Metabolic Defects of Pre-Diabetes and Type 2 Diabetes Mellitus

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2004 to 2008Enrolled70ConditionsDiabetes Mellitus, Type II, Insulin ResistanceArmsExercise cardiopulmonary metabolic testing, Skeletal muscle biopsy, Brachial artery reactivity testing
NCT00486681 completednot on this mapstarted 2007, after this paper: background citation

Evaluation of the Implementation of the Accu-Chek Inform Cobas IT 1000 System in Three Medical Hospital Departments: Impact on the Management of Diabetes

TypeobservationalSponsorUniversity Hospital, GrenobleRan2007 to 2008Enrolled949ConditionsDiabetes Mellitus, Blood Glucose, Hospital Information Systems, Medical DeviceArmsAccu Chek Inform and Cobas IT 1000
NCT00555750 nacompletednot on this mapstarted 2006, after this paper: background citation

The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia

TypeinterventionalSponsorBrigham and Women's HospitalRan2006 to 2008Enrolled20ConditionsPrimary InsomniaArmseszopiclone, placebo
NCT00591903 completednot on this mapstarted 2007, after this paper: background citation

Pilot Study to Assess the Proteome in Human Atrial Tissue

TypeobservationalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2007 to 2011Enrolled600ConditionsDiabetes, Cardiomyopathy
NCT00775684 nacompletednot on this mapstarted 2008, after this paper: background citation

A Randomized, Controlled Trial Comparing the Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass in Patients With Impaired Fasting Glucose or Early Type 2 Diabetes

TypeinterventionalSponsorUniversity of PennsylvaniaRan2008 to 2012Enrolled47ConditionsPre-diabetes, Type 2 DiabetesArmsExenatide, Sitagliptin, Glimepiride
NCT01971125 completednot on this mapstarted 2006, after this paper: background citation

Left Ventricular DYsfunction in DiAbetes

TypeobservationalSponsorHeart Care FoundationRan2006 to 2010Enrolled970ConditionsDiabetes Mellitus, Type 2, Heart Diseases, Left Ventricular Dysfunction
NCT02092870 phase2completednot on this mapstarted 2013, after this paper: background citation

Adipose Derived Regenerative Cellular Therapy of Chronic Wounds

TypeinterventionalSponsorTower Outpatient Surgical CenterRan2013 to 2019Enrolled25ConditionsDiabetic Foot, Venous Ulcer, Pressure UlcerArmsAdipose derived stem cells
NCT02797392 nacompletednot on this mapstarted 2016, after this paper: background citation

Early Detection and Prevention of Lifestyle Related Diseases - a Pilot Study

TypeinterventionalSponsorUniversity of Southern DenmarkRan2016 to 2017Enrolled9,400ConditionsType-2 Diabetes, Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease (COPD)ArmsLifestyle intervention
3 · Its place in the literature

Who cites it

1,225 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

H KingDivision of Noncommunicable Diseases, World Health Organization, Geneva, Switzerland. kingh@who.ch
R E Aubert
W H Herman

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the prevalence of diabetes and the number of people with diabetes who are > or =20 years of age in all countries of the world for three points in time, i.e., the years 1995, 2000, and 2025, and to calculate additional parameters, such as sex ratio, urban-rural ratio, and the age structure of the diabetic population. RESEARCH DESIGN AND

methodsAge-specific diabetes prevalence estimates were applied to United Nations population estimates and projections for the number of adults aged > or =20 years in all countries of the world. For developing countries, urban and rural populations were considered separately

resultsPrevalence of diabetes in adults worldwide was estimated to be 4.0% in 1995 and to rise to 5.4% by the year 2025. It is higher in developed than in developing countries. The number of adults with diabetes in the world will rise from 135 million in 1995 to 300 million in the year 2025. The major part of this numerical increase will occur in developing countries. There will be a 42% increase, from 51 to 72 million, in the developed countries and a 170% increase, from 84 to 228 million, in the developing countries. Thus, by the year 2025, >75% of people with diabetes will reside in developing countries, as compared with 62% in 1995. The countries with the largest number of people with diabetes are, and will be in the year 2025, India, China, and the U.S. In developing countries, the majority of people with diabetes are in the age range of 45-64 years. In the developed countries, the majority of people with diabetes are aged > or =65 years. This pattern will be accentuated by the year 2025. There are more women than men with diabetes, especially in developed countries. In the future, diabetes will be increasingly concentrated in urban areas.

conclusionsThis report supports earlier predictions of the epidemic nature of diabetes in the world during the first quarter of the 21st century. It also provides a provisional picture of the characteristics of the epidemic. Worldwide surveillance of diabetes is a necessary first step toward its prevention and control, which is now recognized as an urgent priority.

Indexed as

AdultAgedDiabetes MellitusFemaleHumansMaleMiddle AgedPrevalenceRural HealthSex RatioUrban Health

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

and 6 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.